New HIV prevention strategy to benefit sufferers by cutting costs
July 8th, 2010 - 5:58 pm ICT by ANIWashington, July 8 (ANI): Increasing highly active antiretroviral therapy (HAART) treatment for people with HIV/AIDS will provide significant cost savings over a relatively short period of time, according to a formal economic analysis.
Led by researchers at the BC Centre for Excellence in HIV/AIDS (BC-CfE) at Providence Health Care and the University of British Columbia (UBC), the analysis of HAART coverage in British Columbia, is the first comprehensive economic evaluation of the net benefit of HAART in the province.
HAART lowers viral load, stopping HIV from progressing to AIDS in individuals and helping to prevent HIV transmission.
The study’s key finding shows that while expanding HAART use is cost-effective for individual patients, the benefits become exponentially greater when HAART’s ability to prevent HIV transmission is considered.
The economic analysis demonstrated that increasing HAART treatment coverage from the current estimated 50 per cent to 75 per cent of all clinically eligible British Columbians (HIV-infected individuals with CD4 cell counts below 350 cells/ ul) would deliver a net benefit of 900 million US Dollars over 30 years.
“The study findings make the point that expansion of HAART is not just a medical or ethical imperative, it is a very smart financial investment in terms of its potential to improve public health,” said Dr. Julio Montaner, director of the BC-CfE, president of the IAS, and one of the authors of the study.
“HIV continues to be a global health concern and the lifetime costs of treating individuals with HIV are substantial. Therefore, HAART’s potential to prevent new HIV infections is an important element of the overall strategy to minimize the economic burden on the health care system of treating HIV,” he added.
Within B.C., the sub-populations most affected by HIV are hard-to-reach, marginalized groups such as sex trade workers, injection drug users and men who have sex with men.
Prevention of new infections among these HIV-vulnerable groups must be a priority in order to meaningfully curb the growth of the epidemic.
In this context, the study findings lend further credence to the BC-CfE-pioneered Seek and Treat strategy.
The Seek and Treat program will improve access to HIV/AIDS treatment and care among hard-to-reach populations.
The study is published in AIDS, the official journal of the International AIDS Society (IAS). (ANI)
- Study reinforces antiretroviral therapy's effectiveness in HIV prevention - Jul 20, 2010
- Increased HAART coverage tied to 50pc drop among injection drug users - Feb 19, 2010
- India to avert 3 million HIV cases: World Bank - Nov 30, 2011
- Mother-to-child HIV transmission on decline in US, but more can be done - Jul 23, 2010
- Aid appeal to combat HIV/AIDS in Myanmar - Dec 06, 2011
- 28,000 die of HIV/AIDS in China - Jan 22, 2012
- Meet on AIDS begins at UN - Jun 08, 2011
- Don't neglect people with HIV, PM tells ministries - Jul 04, 2011
- Treating HIV-AIDS with interleukin-2 'ineffective' - Oct 16, 2009
- AIDS drugs block 99pc of HIV transmission to breastfed babies - Jun 17, 2010
- HIV/AIDS still a serious health problem: WHO - Dec 01, 2010
- Court notice on insurance for AIDS patients - May 12, 2011
- AIDS welfare cost may effect growth: Report - Apr 01, 2011
- Aim to eliminate HIV-AIDS from South-East Asia by 2015: WHO (Dec 1 is World AIDS Day) - Nov 30, 2011
- China to have 1.2 mn HIV-affected people by 2015 - Dec 04, 2010
Tags: active antiretroviral therapy, bc centre, british columbians, economic burden, economic evaluation, ethical imperative, health care system, health concern, hiv aids, hiv infections, hiv prevention strategy, hiv transmission, injection drug users, lifetime costs, marginalized groups, providence health care, sex trade workers, treatment coverage, university of british columbia, viral load